Dear Small Cap Investor:

 We believe BioElectronics Corp. (BIEL) is an excellent small cap pick.  Doing your own homework on the company is easy as there is a wealth of information on the web about the technology and the company and numerous testimonials from leading surgeons, physicians and leading sport trainer who recommend the product.  These testimonials can be seen at http://www.actipatchonline.com/ActiPatch-physicians.html 

BioElectronics Corp. (BIEL) Revolutionizing Healing and Pain Management Poised for Major Revenue Growth in 2008 

Summary BioElectronics Corp. (BIEL) manufacturers an FDA cleared device for treating pain and aiding the healing of soft tissues injuries.  Quite literally, the product often cuts the healing time of cuts, bruises and soft tissue injuries often times by more than half and has been used by plastic surgeons for years.  The efficacy of the technology on which the product is based is well documented in numerous scientific studies.  The product is now being made available to the general public.  The Company spent 2007 reorganizing, improving its products, improving distribution and receiving government approvals FDA, Health Canada, European Union, and others are now completed.  The Company is entering 2008 with significant new products, extensive new distribution, an upcoming Canada-wide drug store launch and has recently signed an aggressive Internet partner for online sales.  BioElectronics is poised for strong revenue growth during the year.  The vast majority of investors have failed to noticed the actions taken by the company and the revenue growth potential likely makes BIEL a near term home run small cap stock pick.  Doing your own homework on the company is easy as there is a wealth of publicly available information about the technology and the company and numerous testimonials from leading surgeons, physicians and leading sport trainer who recommend the product.  These can be seen at http://www.actipatchonline.com/ActiPatch-physicians.html 

The Details - Over the past 100 years medical researchers have made significant progress in treating and curing many diseases and afflictions.  Conditions that only 50 years ago resulted in high rates of mortality can today be cured by taking a simple pill.  These and other medical advances have improved the quality of life for almost every human being on earth.  Even though medical researchers have made great progress in many areas there are still two major areas of medicine where researchers have not been able to make meaningful strides toward effective treatments.  These areas are soft tissue healing and pain management.  

As incredible as it sounds the treatment of soft tissue injury has advanced very little over the past few millenniums.  When we get a cut, a bad bruise or a sprain we typically clean the affected area, wrap it in some type of bandage to stop the bleeding and to prevent infection and then immobilize the injured part of the body.  We then endure the pain and wait while the body slowly recovers and heels.  This process has been pretty much standard operating procedure that has changed little in over a thousand years. 

In the relatively recent past the medical community figured out that the oral administration of chemical compounds, known as non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, would work toward reducing the inflammation and pain associated with the injury and more recently a new class NSAIDs, called COX-2 inhibitors, has been introduced.  While aspirin and ibuprofen are mildly effective on some types of pain there are certainly issues with both short-term and long-term usage.  Because NSAIDs, especially aspirin, reduce blood clotting those who take it will bruise more easily.  Additionally, the risk of developing nausea, an upset stomach, or an ulcer is high as is the possibility of kidney function interference.  The COX-2 inhibitors, such as Celebrex¨ and Vioxx¨, while initially billed as virtual miracle cures have now been proven to meaningful increase the chance of heart attack and are no longer widely available.  For serious injury and pain there are a variety of opiate derived drugs that are very effective in treating pain, but cause serious side effects including possible addiction.  Simply put, for those suffering from pain there are a few acceptable options. 

The questions for investors relative to these subjects are simple.  What if there was a technology that could speed the healing of soft tissue injuries and reduce the associated pain?  What if the US government's Food and Drug Administration (FDA) and other health care related government agencies around the world cleared the technology for use?  What would the company that possesses this technology be worth?  And finally, and most importantly, what is the name of this company? 

We believe the answers to these questions are simple.  Yes, there is a drug-free, technology that speeds healing of soft tissue injuries and significantly reduces pain.  It's called pulsed electromagnetic energy.  Yes, the FDA has recently cleared one company's version of this technology.  The name of the company is BioElectronics Corp., which trades under the stock symbol BIEL.  Finally, what are this technology and this company worth?  We believe both are worth a lot.  Read a little further and we will explain what we are talking about. 

BioElectronics Corp. is the maker of the unique inexpensive, drug-free, anti-inflammatory patch designed to reduce pain and swelling (edema) and accelerate healing.  The company's product is called ActiPatch™.  It is FDA cleared.  The product is based on the same proven and highly effective pulsed electromagnetic therapy use for decades by physicians, therapists and athletic trainers worldwide.  The inventors of ActiPatch have used state-of-the-art microelectronic circuitry to shrink the technology into an expensive, small, wafer thin, lightweight wearable patch that effectively reduces swelling (edema) and significantly speeds the healing process with no known side effects.   

The process by which ActiPatch works is complex and beyond the scope of this report, but put simply, the very small amount of electromagnetic energy produced by the patch breaks the chronic cycle of inflammation caused by soft tissue injury in only a few days of therapy allowing the body to speed up its own natural healing process.  Acute sprains usually respond within hours of initial therapy to relieve pain and restore functionality.  The healing time from cuts and bruises is significantly reduced through the use of the product and has been proven in multiple scientific papers by leading physicians, plastic surgeons and universities. 

The research on the effectiveness of the technology on which this product is based is overwhelming and supported by multiple scientific studies.  BioElectronics' product has received FDA market clearance for the treatment of edema following blepharplasty, has been approved by Health Canada for relief of pain in musculoskeletal complaints and is widely available over-the-counter in pharmacies, and the European Union has granted the product its coveted CE Mark certification for the medical and retail over the counter markets.  

For the past few years BioElectronics Corp. has been working to bring its product to market and spent most of 2007 establishing its distribution channels.  The product has recently become available online without a physician's office visit at www.actipatchonline.com  The company now has more than 70 domestic independent sales agents, over 20 international distributors, a medical research partnership with the world-famous Lehey Clinic, a solid intellectual property portfolio and significant endorsements from leading physicians, plastic surgeons, athletic trainers and hundreds of satisfied users of the product.  But you don't have to take our word for it.  Many of these endorsements can be seen on the web at www.actipatchonline.com. 

The company's President and CEO recently issued a shareholder letter outlining developments in 2007 and how the organization is positioned for strong growth in 2008.  Over the past year the company has restructured its management team, introduced many new retail oriented products, made improvements to the plastic and general surgery product line, transferred all of its manufacturing operations offshore, which will likely allow for production costs to fall below 20% of retail pricing, has launched its products in large markets such as Italy, Mexico, United Kingdom, the Netherlands, among others.  We believe the market for the company's products is huge.  It is estimated that the market for therapeutic agents for the treatment of and the pain associated with soft tissue injuries is valued in excess of $10 Billion worldwide.  

We see 2008 as the year BioElectronics' revenues explode and profitability is obtained.  With fewer than 150 million outstanding shares the market capitalization of this emerging leader in an untapped multibillion-dollar market is currently well less than $5 million.  We believe this market valuation will rise significantly as the market realizes this company is moving from developmental stage into revenue and earnings production stage.  Stay tuned to this story as it appears the company has a significant string of upcoming events that are likely to impress small-cap investment community.  More information about BioElectronics Corp. can be obtained at www.bioelectronics.com and www.actipatchonline.com

Thank You,

Joseph A. Noel

Emerging Growth Research

jnoel@emerginggrow.com

Analyst and Other Important Disclosures

Analyst Certification - I, Joseph Noel, hereby certify (1) that the views expressed in this research company report accurately reflect my personal views about any or all of the subject securities or issuers referred to in this company report and (2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this company report.

Analyst:

Joseph Noel is a 28-year veteran of the high tech and investment industries and is currently an independent stock analyst.  Joe was recently a senior analyst at Pacific Growth Equities, LLC, where he tracked the communications equipment/services and advanced industrial sectors. Prior to Pacific Growth, he covered both the telecommunications equipment and services industries at Hambrecht & Quist and was employed by Gartner/Dataquest as a communications industry analyst. Before becoming an analyst, Mr. Noel received solid industry experience at a number of major corporations, including Mc Donald Douglas, MCI, AT&T, and British Telecom, where he was involved in strategic planning for the company's Internet access service.  Mr. Noel received his MBA in finance from Wake Forest University, and holds a BS in business and economics. A four-time Wall Street Journal All-Star Analyst, Joe specializes in emerging growth companies in the health care, communications, Internet and advanced industrial equipment sectors.

Information, opinions, or recommendations contained in this research report are submitted solely for informational purposes. The information used in statements of fact made has been obtained from sources considered reliable, but we neither guarantee nor represent their completeness or accuracy. Such information and the opinions expressed are subject to change without notice. This research report is not intended as an offering or a solicitation of any offer to buy or sell the securities mentioned or discussed. The firm, its principles, or the assigned analyst may or may not own or trade shares, options, or warrants of this covered company.  Emerging Growth Research, LLP, has NOT received, and will not receive, monetary compensation for the production of this report.  Additionally, the analyst responsible for the production of this report owns common stock and/or warrants in the subject company. The views expressed in this research company report accurately reflect the analyst's personal views about any or all of the subject securities or issuers referred to in this company report, and no part of the analyst's or the firm's compensation was, or will be directly or indirectly related to the specific recommendation or views expressed in this report.  Opinions expressed herein reflect the opinion of Emerging Growth Research, LLP and are subject to change without notice.  We claim no responsibility to update the information contained in this report. Investors should consider the suitability of any particular investment based on their ability to accept certain levels of risk, and should not rely solely on this report for information pertaining to the company covered. The material in this document is intended for general circulation only and the recommendations contained herein do not take into account the specific objectives, financial situation, or particular needs of any particular person.  An investor should consult his investment representative regarding the suitability of this investment and take into account any specific investment objectives, financial situation, or particular needs before he or she makes a commitment to purchase the shares of this or any other company's stock.  No part of this document may be reproduced in any manner without the written permission of Emerging Growth Research, LLP.

 RECENT NEWS RELEASE